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Abstract
Background
Animal embryotoxicity data, and the scarcity of safety data in human pregnancies, have pre-
vented artemisinin derivatives from being recommended for malaria treatment in the first tri-
mester except in lifesaving circumstances. We conducted a meta-analysis of prospective
observational studies comparing the risk of miscarriage, stillbirth, and major congenital
anomaly (primary outcomes) among first-trimester pregnancies treated with artemisinin
derivatives versus quinine or no antimalarial treatment.
Methods and findings
Electronic databases including Medline, Embase, and Malaria in Pregnancy Library were
searched, and investigators contacted. Five studies involving 30,618 pregnancies were
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included; four from sub-Saharan Africa (n = 6,666 pregnancies, six sites) and one from Thai-
land (n = 23,952). Antimalarial exposures were ascertained by self-report or active detection
and confirmed by prescriptions, clinic cards, and outpatient registers. Cox proportional haz-
ards models, accounting for time under observation and gestational age at enrollment, were
used to calculate hazard ratios. Individual participant data (IPD) meta-analysis was used to
combine the African studies, and the results were then combined with those from Thailand
using aggregated data meta-analysis with a random effects model.
There was no difference in the risk of miscarriage associated with the use of artemisinins
anytime during the first trimester (n = 37/671) compared with quinine (n = 96/945; adjusted
hazard ratio [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%, p = 0.228), in the risk of stillbirth (arte-
misinins, n = 10/654; quinine, n = 11/615; aHR = 0.29 [95% CI 0.08–1.02], p = 0.053), or in
the risk of miscarriage and stillbirth combined (pregnancy loss) (aHR = 0.58 [95% CI 0.36–
1.02], p = 0.099). The corresponding risks of miscarriage, stillbirth, and pregnancy loss in a
sensitivity analysis restricted to artemisinin exposures during the embryo sensitive period
(6–12 wk gestation) were as follows: aHR = 1.04 (95% CI 0.54–2.01), I2 = 0%, p = 0.910;
aHR = 0.73 (95% CI 0.26–2.06), p = 0.551; and aHR = 0.98 (95% CI 0.52–2.04), p = 0.603.
The prevalence of major congenital anomalies was similar for first-trimester artemisinin
(1.5% [95% CI 0.6%–3.5%]) and quinine exposures (1.2% [95% CI 0.6%–2.4%]). Key limita-
tions of the study include the inability to control for confounding by indication in the African
studies, the paucity of data on potential confounders, the limited statistical power to detect
differences in congenital anomalies, and the lack of assessment of cardiovascular defects in
newborns.
Conclusions
Compared to quinine, artemisinin treatment in the first trimester was not associated with an
increased risk of miscarriage or stillbirth. While the data are limited, they indicate no differ-
ence in the prevalence of major congenital anomalies between treatment groups. The bene-
fits of 3-d artemisinin combination therapy regimens to treat malaria in early pregnancy are
likely to outweigh the adverse outcomes of partially treated malaria, which can occur with
oral quinine because of the known poor adherence to 7-d regimens.
Review registration
PROSPERO CRD42015032371
Author summary
Why was this study done?
• Malaria infection is more frequent and severe in pregnant women compared to non-
pregnant women, and the adverse consequences of malaria in pregnancy require
prompt, safe, and effective treatment.
• Artemisinin combination therapies (ACTs), the most efficacious antimalarials available,
are the recommended first-line treatment for Plasmodium falciparum malaria.
Meta-analysis of the safety of artemisinin and quinine in first trimester
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• Animal embryotoxicity data and the paucity of safety data in human pregnancies have
prevented artemisinin derivatives from being recommended for malaria treatment in
the first trimester except in life-saving circumstances, yet in malaria endemic countries,
many early pregnancies are advertently or inadvertently exposed to ACTs.
• In this meta-analysis of prospective observational studies, we summarize all available
safety data on the effect of artemisinin exposure in the first trimester and compare the
risk of miscarriage, stillbirth, and major congenital anomaly for pregnancies treated
with artemisinin, quinine, or no antimalarials in the first trimester.
What did the researchers do and find?
• Our team determined the risk of miscarriages, stillbirths, and major congenital anoma-
lies associated with first-trimester artemisinin treatment versus quinine in four indepen-
dent prospective observational studies across six sites in sub-Saharan Africa using
individual participant data meta-analysis. The results were then combined with sum-
mary effect estimates from the Shoklo Malaria Research Unit on the Thailand–Myan-
mar border using aggregated data meta-analysis.
• We found no difference in the risk of miscarriage, stillbirth, or major congenital anoma-
lies associated with the use of artemisinins anytime during the first trimester compared
with the use of quinine during the same gestational period.
What do these findings mean?
• The ACT class of antimalarials should be considered for treatment of malaria in the first
trimester of pregnancy.
• The limited data on the risk of congenital anomalies require further observational
studies.
Introduction
Artemisinin combination therapies (ACTs), the most efficacious antimalarials available, are
the recommended first-line treatment for Plasmodium falciparum malaria except in the first
trimester of pregnancy [1]. Preclinical studies have demonstrated that artemisinin derivatives
are embryotoxic and can induce fetal death and congenital anomalies at doses close to the ther-
apeutic range in multiple animal species [2–10]. In rodents, artemisinins cause embryolethality
as well as cardiovascular (ventricular septal and vessel defects) and skeletal defects (shortened
or bent long bones and scapulae, misshapen ribs, cleft sternebrae, and incompletely ossified
pelvic bones) [6]. In monkeys, embryolethality was observed following prolonged treatment
(12 to 20 d), but there were no malformations [2,4]. The artemisinin embryotoxic effect occurs
through depletion of embryonic erythroblasts [11]. It is unknown how findings from animal
studies would translate in humans because the mechanism of teratogenicity and the drug sen-
sitive period may differ significantly in humans [3,12]. The last review by the World Health
Meta-analysis of the safety of artemisinin and quinine in first trimester
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1002290 May 2, 2017 3 / 20
Organization (WHO) dates from 2006, when evidence on 170 human first-trimester artemisi-
nin treatments was reassuring but insufficient to inform policy change [13]. Consequently,
quinine remains the recommended treatment for uncomplicated P. falciparum malaria in the
first trimester. Presently, artemisinins are recommended in the first trimester only if quinine
cannot be used or in cases of severe malaria where the benefit outweighs the potential risk.
Weighing the risks and benefits of artemisinin treatment in the first trimester is important for
public health policy as well as for individual treatment decisions. Malaria is more frequent and
severe in pregnant women compared to non-pregnant women [14–16]. Because of the adverse
consequences of malaria in pregnancy, prompt, safe, and effective treatment is required [17,18].
Concerns over the efficacy, tolerance, adherence, and availability of quinine calls for a reconsider-
ation of its risk–benefit balance relative to ACTs [19,20]. Malaria infection in the first trimester
leads to placental infection associated with maternal anemia, low birth weight, and intrauterine
growth retardation [17,21,22]. First-trimester malaria documented on the Thailand–Myanmar
border was strongly associated with miscarriage, especially following recurrence of infection
[23,24]. Malaria-associated risks must be balanced with any safety risks due to treatment. The
assessment of treatment risk during pregnancy is complex and requires detection and confirma-
tion of (1) malaria, (2) antimalarial treatment in the first trimester, and (3) adverse outcomes, and
this complexity has implications for the management of confounding factors in statistical analy-
ses. Case–control studies can be useful and efficient for assessing drug safety signals; however, this
approach is not recommended for pregnancy outcomes due to the high risk of recall bias [25].
To compare the potential harm versus beneficial impact on pregnancy outcomes of treat-
ment with artemisinin derivatives versus quinine, we determined the risk of miscarriage, still-
births, and major congenital anomalies associated with first-trimester artemisinin treatment in
four independent prospective observational studies across six sites in sub-Saharan Africa using
individual participant data (IPD) meta-analysis [26] and combined the results with summary
effect estimates from the Shoklo Malaria Research Unit (SMRU) at the Thailand–Myanmar
border, using aggregated data meta-analysis.
Methods
Ethics
All studies had institutional ethical review approvals and obtained informed consent from all
participants. The institutional ethics review committees for the individual studies are listed in
S2 Text.
Search strategy
The protocol for this meta-analysis was registered on PROSPERO (CRD42015032371). We
report our findings in accordance with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) checklist of items specific to IPD meta-analyses (S1 Checklist) [27].
We conducted an electronic search of Medline, Embase, and the Malaria in Pregnancy
Library as of November 16, 2015, using the PICOTS (patient, intervention, comparator, out-
come, timing, and setting) framework (S1 Text) [28]. We also searched trial registries, “gray lit-
erature” databases, and conference abstracts; manually reviewed reference lists of selected
publications; and contacted experts in the field to get information on unpublished studies.
Inclusion/exclusion criteria
Studies were eligible if (1) the study reported artemisinin derivative use in the first trimester
of pregnancy, (2) antimalarial treatment was confirmed through multiple data sources, (3)
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women were enrolled before pregnancy outcome was known (i.e., prospective follow-up of
pregnancy), and (4) the study included internal comparison groups with either quinine treat-
ment or no antimalarial treatment in the first trimester. Studies were excluded if they were
case series, retrospective or case–control studies, or cross-sectional surveys; did not involve
artemisinins treatment; reported only second and third trimester artemisinin exposures; or
did not report pregnancy outcomes (S3 Text).
Data extraction and compilation
The first author or principal investigator of each study was invited to participate in the pooled
analysis and was asked to provide individual-level data (S1 Text). The data requested included
relevant baseline characteristics, gestational age, antimalarial exposure information, pregnancy
outcomes, and congenital anomalies.
Risk of bias assessment
The Newcastle–Ottawa scale for assessing bias in cohort studies was used [29] to assess the
IPD studies with respect to the selection of the artemisinin, quinine, and untreated groups; the
comparability of the groups; and the ascertainment of the outcomes of interest, including loss
to follow-up (see S2 Text for ratings of each study for the IPD analysis).
Antimalarial exposure group definitions
Exposures were considered confirmed if information could be verified across at least two data
sources (self-reported by the woman and confirmed from clinic cards, outpatient registers, or
prescription sheets or directly observed/documented by concurrent independent surveillance
in Kenya [30]). Otherwise, treatments were classified as unconfirmed and excluded from the
analysis. The treatments of interest were artemisinin derivatives or quinine in the first trimes-
ter of pregnancy (13 wk from the date of the last menstrual period). For the IPD studies,
pregnancies were considered unexposed if there was no evidence (including unconfirmed
exposures) of antimalarial treatment up to 18 wk gestation; in the SMRU analysis, unexposed
pregnancies were pregnancies without microscopically confirmed malaria and without anti-
malarial treatment in the first trimester. Further details on the exposure definitions used for
the IPD and SMRU analyses are provided in S3 Text.
Outcome definitions
The primary outcomes of interest were (1) miscarriage, defined as a confirmed pregnancy
(identified by pregnancy test or ultrasound and/or examination at antenatal care visit) that
ended at or before 28 wk gestation; (2) stillbirth, defined as fetal death after 28 wk gestation in
utero or during labor, and (3) major congenital anomaly, defined as any structural abnormal-
ity with surgical, medical, or cosmetic importance detected by surface examination at birth. In
addition, cases with two or more minor anomalies were considered as major congenital anom-
aly for the African sites, as per the Antiretroviral Pregnancy Registry guidelines. An expert
birth defect panel established by the WHO Pregnancy Registry pilot project [31], the WHO
Birth Defect Panel, independently and blinded to exposure status, reviewed and classified all
the congenital anomalies from three sites under a multicenter study protocol, the Assessment
of the Safety of Antimalarial Drug Use during Early Pregnancy (ASAP) study. For the other
studies, criteria to differentiate between major and minor anomalies and to determine anoma-
lies for exclusion, such as genetic and chromosomal disorders, were applied based on the
WHO Birth Defect Panel recommendations and published criteria [32]. Data from Rwanda
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were not included in the analysis of congenital anomalies as only major anomalies were
reported, and two out of the six anomalies were detected in participants enrolled after delivery.
Data analysis
The data analysis was prespecified in an analytical plan (S1 Text). Statistical analyses were per-
formed in Stata version 13.1, R version 3.2.1, and SAS version 9.4. Further details on statistical
methods are provided in S4 Text.
The primary analysis compared pregnancies with a confirmed treatment with artemisinin
to pregnancies with a confirmed treatment with quinine. A secondary analysis compared mis-
carriage, stillbirth, and major congenital anomaly in women treated with artemisinin or qui-
nine to those in women who did not have malaria in the first trimester. In Africa, it was
assumed that a woman did not have malaria if she did not receive antimalarials; in Asia, not
having malaria was microscopically confirmed by repeated screens.
Individual participant data check and missing data
Data were re-coded as necessary to create a pooled dataset for analysis purposes. The integrity
of the data was checked by comparing the data in published reports with the data provided, as
well as through review of internal out-of-range inconsistencies. In case of discrepancies, the
investigators were contacted for clarification. Women for whom pregnancy outcome was
unknown were considered lost to follow-up. These women were included in the analysis and
contributed person-time until the last visit date when they were censored. Missing values were
included as “unknown” categorically.
Individual participant data statistical approach
IPD estimates were for women who received first-line quinine or first-line artemisinin treat-
ment for uncomplicated falciparum malaria in the first trimester, and excluded women with
unknown gestational age, women who received more than one antimalarial treatment in the
first trimester, those recruited at or after pregnancy outcome, and those with an unconfirmed
antimalarial exposure (Fig 1).
For the miscarriage and stillbirth endpoints, hazard ratios (HRs) and 95% confidence inter-
vals (CIs) were estimated using Cox regression models to account for time under observation
and different gestational age at enrollment. Exposure was treated as time-dependent so that par-
ticipants were considered exposed only from the time they received artemisinin or quinine
treatment rather than from the time of enrollment in the study. The estimated log HRs were
combined across studies using one-stage random effects meta-analysis adjusting for clustering
by study site, along with assessment of heterogeneity. Heterogeneity across studies was assessed
using I2 for both one-stage and two-stage IPD analysis. The proportional hazards assumptions
of the Cox model were evaluated by testing for interactions between our time-varying exposures
of interest and the logarithm of follow-up time, and further examined using log (−log[survival])
versus log of survival time plots. To account for the correlation between pregnancies for women
with more than one pregnancy within a study, a robust variance estimator was used. All crude
effect estimates in the IPD analysis were site-adjusted. In addition we conducted multivariate
analyses adjusting for potential confounders identified a priori and available from all sites (gra-
vidity and age). Adjusted models do not include HIV status as it is likely missing not at random
with respect to antimalarial treatment and miscarriage (missing for 8% of participants and for
40% of those with a miscarriage). Descriptive statistics were used to classify congenital anoma-
lies using the Antiretroviral Pregnancy Registry Organ System Classification [33]. Pooled preva-
lence of major congenital anomaly and its 95% confidence interval were estimated through
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Fig 1. Flow diagram of studies and participants included in meta-analysis for miscarriage, stillbirth, and congenital
anomaly. ACT, artemisinin combination therapy; ANC, antenatal care; IPD, individual participant data.
https://doi.org/10.1371/journal.pmed.1002290.g001
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inverse weighting of variance and random effects, with 0.05 continuity correction for zero
count frequencies.
Aggregated data meta-analysis
For miscarriage and stillbirth, aggregated data were pooled and combined into summary HRs
using a Mantel–Haenszel random effects model combining the IPD analysis from the African
sites with effect estimates from Asia. Effect estimates from the SMRU were based on a similar
Cox regression model accounting for left truncation and treating antimalarial treatment as
time-dependent as described in a recently published report [24]. SMRU estimates were for
women who presented to antenatal clinics during their first trimester with a viable fetus and
included uncomplicated, hyperparasitemic, and severe malaria and pregnancies with multiple
malaria episodes. Multivariate analyses adjusted for infection severity (asymptomatic, symp-
tomatic, hyperparasitemic/severe), year of first consultation, and non-malaria febrile morbid-
ity in first trimester. HIV was not accounted for, but the prevalence on the Thailand–
Myanmar border is very low [34]. Count data on major congenital anomalies by organ system
were used to derive pooled prevalence estimates for exposure groups. A summary of inclusion
and exclusion criteria for the SMRU and for the African site IPD is provided in S3 Text.
Sensitivity analysis
Animal reproductive toxicity studies suggest that the embryo sensitive period in humans for
artemisinins is between 4 and 10 wk post-conception (6–12 wk after last menstrual period)
[11,12]. Therefore, we conducted sensitivity analyses to explore the effect of restricting the
analysis to treatments that occurred in the embryo sensitive period for artemisinin. The effect
size should be highest for treatments restricted to that embryo sensitive period if the embryo-
toxicity mechanism hypothesized from animal models applies to humans. Additional sensitiv-
ity analyses were performed to assess (1) the robustness of the results when using a two-stage
IPD meta-analysis approach, (2) removing one site at a time from the meta-analysis and test-
ing the effect of each study on the pooled estimates, and (3) the effect of imputation and strati-
fied analysis by HIV status given the high proportion of miscarriage cases with unknown HIV
status in the IPD from the African sites.
Post hoc multivariate network meta-analysis
Following a suggestion by one of the reviewers, we also conducted multivariate network meta-
analysis to evaluate the combined effect of artemisinins on miscarriage and stillbirth (preg-
nancy loss) while accounting for the correlation structure between these two outcomes [35,36]
(see S4 Text).
Results
Twenty-seven studies were identified, of which seven were eligible and five were included in
the analysis: four from sub-Saharan Africa and one from the SMRU in Thailand [23] (Figs 1
and S1). The four African studies included a study conducted in three sites under a single mul-
ticenter study protocol (ASAP study) [35] and three additional stand-alone studies [36–38].
The excluded studies included one multi-country study coordinated by WHO [31] for
which the analysis was still ongoing and one prospective cohort study from Indonesia [39] that
met the inclusion criteria but was excluded due to systematic bias by indication: dihydroarte-
misinin-piperaquine was prescribed selectively for the sicker patients, as reported in the pub-
lished paper.
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Characteristics of the individual participant data studies
All contacted investigators agreed to participate and sent the complete, anonymized individ-
ual-level data of their respective studies following completion of a data sharing agreement.
Data from four prospective cohort studies contributed to the IPD meta-analysis, with the num-
ber of pregnancies included in the analysis depending on the outcome (Table 1). The studies
were conducted in six countries in sub-Saharan Africa (Zambia, Tanzania, Rwanda, Kenya,
Mozambique, and Burkina Faso) between 2004 and 2013. Description of participant character-
istics across exposure categories for participants included in the IPD analysis is presented in
Table 2. For discrepancies between data included in this IPD analysis and published reports,
see S5 Text.
Table 1. Description of prospective cohort studies and data included in the African individual participant data meta-analysis and Asian aggre-
gated data meta-analysis.
Study Study site Study
period
Mean
gestational
age at
enrollment
(SD)
Mean
gestational
weeks of
follow-up
(SD)
Number of
confirmed
first
trimester
artemisinin
treatments
Number of
confirmed
first-
trimester
quinine
treatments
Number with
no
antimalarials
in first
trimestera
Number of
miscarriages
Number
of
stillbirths
Number
of live
births
Africa
Manyando
et al. [36]
Zambia 2004–
2008
25.1 (8.1) 13.7 (8.1) 179 4 632 9 17 754
Rulisa
et al. [38]
Rwanda 2007–
2009
26.9 (8.0) 11.4 (7.6) 77 0 1,515 12 47 1,533
Mosha
et al. [37]
Tanzania 2012–
2013
14.6 (3.5) 20.1 (11.1) 156 69 1,533 41 61 1,656
Dellicour
et al. [30];
Tinto et al
[35]
Kenyab 2011–
2013
15.5 (8.9) 20.4 (10.7) 64 3 993 62 23 880
Tinto et al.
[35]
Mozambiqueb 2011–
2013
21.0 (5.7) 17.8 (10.3) 24 5 721 13 19 691
Tinto et al.
[35]
Burkina
Fasob
2011–
2013
23.2 (6.8) 14.6 (6.3) 34 24 632 6 13 671
Total all
IPD
2004–
2013
20.8 (8.7) 15.1 (9.3) 534c 105 6,027 143 180 6,185
Asia
Moore [24] Thailand–
Myanmar
border
1994–
2013
9.0 (2.6) 183d 842 22,927 2,257 185 18,537
Total all
studies
Africa and
Asia
1994–
2013
11.5 (3.5) 717 947 28,954 2,400 365 24,722
All women were recruited prospectively before pregnancy outcome was known, but a combination of prospective and retrospective approaches were used
to assess antimalarial exposure information. The numbers represent the total number of enrolled pregnancies; however, varying inclusion/exclusion criteria
were applied for the analyses of the various outcomes, and the numbers vary accordingly.
aUnexposed to any antimalarial up to gestational week 18 for the African sites and up to gestational week 14 for the Thailand–Myanmar border.
bThese three sites were part of a multicenter study, the ASAP study, coordinated by the Malaria in Pregnancy Consortium, using a standard protocol and
with a planned IPD analysis.
cArtemisinin treatment: 501 artemether-lumefantrine and 33 artesunate-amodiaquine (Burkina Faso).
dArtemisinin treatment: 71 mefloquine-artesunate, 50 artesunate-clindamycin, 49 artesunate monotherapy, 10 artemether-lumefantrine, and 3
dihydroartemisinin-piperaquine.
IPD, individual participant data; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002290.t001
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Inclusion of data from Asia in the aggregated data meta-analysis
Aggregated data from the SMRU was included for the assessment of miscarriages, stillbirths,
and major congenital anomalies (detailed description of the site and methods is published in
[24]). There were no stillbirths in the women treated with artemisinin in the first trimester,
and therefore there are no SMRU estimates for that group.
Miscarriage
Pregnancies treated with an artemisinin derivative in the first trimester were at a similar risk
of miscarriage compared to those treated with quinine in the same period (exposure anytime
in the first trimester: adjusted HR [aHR] = 0.73 [95% CI 0.44, 1.21], I2 = 0%; exposure during
Table 2. Descriptive characteristics of pregnancies across exposure categories for the African sites contributing to the individual patient data
meta-analysis.
Characteristic All pregnancies,
n = 6,666
No antimalarial use first
trimester, n = 6,027
Confirmed ACT use first
trimester, n = 534
Confirmed quinine use first
trimester, n = 105
Age (years)
Mean (SD) 26.1 (6.4) 26.1 (6.4) 25.9 (6.2) 25.6 (5.9)
<20 y 1,071 (16.1) 975 (16.2) 76 (14.2) 20 (19.1)
20–24 y 1,961 (29.4) 1,754 (29.1) 180 (33.7) 27 (25.7)
25–29 y 1,697 (25.5) 1,541 (25.6) 122 (22.9) 34 (32.4)
30+ y 1,937 (29.0) 1,757 (29.2) 156 (29.2) 24 (22.9)
Gravidity
Primigravida 1,695 (25.4) 1,505 (25.0) 154 (28.8) 36 (34.3)
1–3 pregnancies 3,269 (49.0) 2,964 (49.2) 255 (47.8) 50 (47.6)
4+ pregnancies 1,570 (23.6) 1,429 (23.7) 124 (23.2) 17 (16.2)
Missing 132 129 1 2
Marital status
Single 828 (12.4) 768 (12.7) 51 (9.6) 9 (8.6)
Married or living together 3,340 (50.1) 3,031 (50.3) 218 (40.8) 91 (86.7)
Missing 2,498 2,228 265 5
Education
Primary not completed 1,583 (23.8) 1,464 (24.3) 92 (17.2) 27 (25.7)
Primary completed 2,475 (37.1) 2,183 (36.2) 236 (44.2) 56 (53.3)
Secondary completed 944 (14.2) 799 (13.3) 124 (23.2) 21 (20.0)
Missing 1,664 1,581 82 1
HIV status
Negative 5,694 (85.4) 5,125 (85.0) 471 (88.2) 98 (93.3)
Positive 567 (8.5) 528 (8.8) 37 (6.9) 2 (1.9)
Missing 405 374 26 5
Gestational age in weeks at
enrollment
Mean (SD) 20.8 (8.7) 21.4 (8.6) 15.2 (7.7) 14.6 (5.1)
Median (IQR) 19 (14–27) 20 (16–28) 13 (10–19) 14 (12–17)
Duration of follow-up in
weeks
26.1
Mean (SD) 15.1 (9.3) 14.8 (9.3) 18.2 (8.9) 22.1 (6.6)
Median (IQR) 14 (8–20) 13 (8–20) 18 (11–25) 23 (19–26)
Data are n (percent) unless otherwise indicated.
ACT, artemisinin combination therapy; IQR, interquartile range; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1002290.t002
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artemisinin embryo sensitive period: aHR = 1.04 [95% CI 0.54, 2.01], I2 = 0%; Fig 2). Pregnan-
cies treated with quinine during the first trimester were associated with significantly increased
risk of miscarriage compared with pregnancies not treated with an antimalarial (aHR = 1.48
[95% CI 1.18, 1.86]). Pregnancies treated with artemisinins during the first trimester were not
associated with an increased risk of miscarriage compared with pregnancies not treated with
an antimalarial (aHR = 1.16 [95% CI 0.81–1.66]; Fig 2).
Stillbirth
There were no differences in the risk of stillbirth for pregnancies treated with an artemisinin
compared to those treated with quinine anytime in the first trimester or during the embryo
sensitive period (aHR = 0.29 [95% CI 0.08, 1. 02] and 0.73 [95% CI 0.26, 2.06], respectively; Fig
3). Neither treatment with an artemisinin nor quinine was associated with an increased risk of
stillbirths compared to pregnancies without any antimalarial treatment in the first trimester:
aHR = 0.65 (95% CI 0.34, 1.23) and 1.35 (95% CI 0.69, 2.65), respectively.
Multivariate meta-analysis
Multivariate meta-analysis for the adverse outcomes of miscarriage and stillbirth (i.e., preg-
nancy loss) also demonstrated no significant differences in risk for pregnancies treated with
Fig 2. Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial
exposure categories and miscarriage. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent
variable. I2 values are for IPD from Africa only: a26.4%; b26.0%; c23.9%; d30.5%; e26.1%; f28.9%. Crude HRs are adjusted for clustering by site in the IPD
arm. aHRs for IPD from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and
non-malaria febrile morbidity in first trimester for the comparison with the unexposed group, while the comparison between the artemisinin and quinine
groups accounts for infection severity (asymptomatic, symptomatic, hyperparasitemic/severe), year of first consultation, and non-malaria febrile morbidity in
the first trimester. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU, Shoklo Malaria Research Unit.
https://doi.org/10.1371/journal.pmed.1002290.g002
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artemisinins compared to those treated with quinine (anytime during the first trimester:
aHR = 0.58 [95% CI 0.36, 1.02], p = 0.099; embryo sensitive period: aHR = 0.98 [95% CI 0.52,
2.04], p = 0.603).
Congenital anomalies
The pooled prevalence of major congenital anomaly among children born to women exposed
to artemisinin and quinine anytime in the first trimester was 1.5% (95% CI 0.6%, 3.5%), and
1.2% (95% CI 0.6%, 2.4%), respectively, and was 2.4% (95% CI 0.9%, 6.1%) and 1.5% (95% CI
0.8%, 3.0%), respectively, for those exposed during the embryo sensitive period. Pooled preva-
lence of major congenital anomaly was 0.7% (95% CI 0.4%, 1.2%) for pregnancies unexposed
to any antimalarial during the first trimester (S6 Table). There was no difference in the distri-
bution of congenital anomalies across organ system classes between treatment groups, but
numbers were small. Details on the distribution of minor and major congenital anomalies are
provided in Table 3.
Sensitivity analysis
Results from the sensitivity analysis are available in S1–S4 Figs and S1 Table. Results from the
two-stage IPD meta-analysis for the African sites showed effect estimates for both miscarriage
Fig 3. Forest plot for aggregated data meta-analysis of crude and adjusted hazard ratios for the association between different antimalarial
exposure categories and stillbirth. HRs account for pregnancy week under observation through left truncation and treat exposure as a time-dependent
variable. I2 values are for IPD from Africa only: a26.0%; b27.4%; c26.1%; d28.3%; e20.5%; f27.0%. Crude HRs are adjusted for clustering by site. aHRs for IPD
from Africa account for site, woman’s age, and gravidity. aHRs for the SMRU account for smoking, year of first consultation, gravidity, and non-malaria febrile
morbidity in the first trimester for the comparison with the unexposed group. aHR, adjusted hazard ratio; HR, hazard ratio; IPD, individual patient data; SMRU,
Shoklo Malaria Research Unit.
https://doi.org/10.1371/journal.pmed.1002290.g003
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and stillbirth similar to those from the one-stage IPD meta-analysis, although with slightly
higher HRs and wider confidence intervals as certain sites no longer contributed data due to
non-events. No difference between treatment groups was observed in this two-stage IPD anal-
ysis, as for the one-stage IPD analysis (first-trimester ACT versus quinine: aHR = 0.64 [95% CI
0.14, 3.04], p = 0.577, for miscarriage and aHR = 0.12 [95% CI 0.01, 3.02], p = 0.196, for still-
birth; S2 Fig and S3 Fig, respectively). The sensitivity analysis examining the effect of removing
one study site at a time on the overall aggregated effect estimates showed that the effect esti-
mates were stable, with minimal variation due to exclusion of individual sites (aHRs for first-
trimester ACT versus quinine ranged from 0.51 when Thailand data were omitted to 0.94
when Tanzania data were omitted, and none were statistically different; S4 Fig). The associa-
tion between miscarriage and first-trimester quinine treatment compared with no antimalarial
treatment was no longer significant when data from Thailand were omitted (aHR = 2.12 [95%
CI 0.76, 5.94], p = 0.153). Effect estimates from models adjusting for HIV status in the African
site IPD—by including individuals with missing HIV status in an “unknown” category or by
using multiple imputation—were similar (within 15%) to the effect estimate adjusting for age
and gravidity only for the primary analysis (comparison between artemisinin and quinine
Table 3. Summary of the distribution of minor and major congenital anomalies by Antiretroviral Pregnancy Registry Organ System Classification
across exposure groups.
Anomalies First trimester Embryo sensitive perioda Total,
n = 24,396No antimalarial,
n = 23,104
Artemisinin,
n = 551
Quinine,
n = 741
Artemisinin,
n = 387
Quinine,
n = 569
Organ system class
Central nervous system 37 (0.16) 0 (0.00) 1 (0.13) 0 (0.00) 1 (0.18) 38 (0.16)
Face and neck 33 (0.14) 3 (0.54) 0 (0.00) 2 (0.52) 0 (0.00) 36 (0.15)
Cleft lip and/or palate 0 (0.00) 0 (0.00) 1 (0.13) 0 (0.00) 1 (0.18) 1 (0.00)
Heart–other defects 4 (0.02) 0 (0.00) 1 (0.13) 0 (0.00) 1 (0.18) 5 (0.02)
Circulatory system–other defects 13 (0.06) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 13 (0.05)
Respiratory system 2 (0.01) 1 (0.18) 0 (0.00) 1 (0.26) 0 (0.00) 3 (0.01)
Upper gastrointestinal system 0 (0.00) 0 (0.00) 2 (0.27) 0 (0.00) 2 (0.35) 2 (0.01)
Gastrointestinal system unspecified 59 (0.26) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 59 (0.24)
Female genitalia 3 (0.01) 1 (0.18) 0 (0.00) 1 (0.26) 0 (0.00) 4 (0.02)
Male genitalia 3 (0.01) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 3 (0.01)
Genitalia unspecified 19 (0.08) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 19 (0.08)
Renal and urinary system 7 (0.03) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 7 (0.03)
Limb reduction/addition defects 9 (0.04) 1 (0.18) 0 (0.00) 1 (0.26) 0 (0.00) 10 (0.04)
Musculoskeletal–other defects 59 (0.26) 1 (0.18) 4 (0.54) 0 (0.00) 4 (0.70) 64 (0.26)
Skin and skin derivatives 7 (0.03) 2 (0.36) 0 (0.00) 2 (0.52) 0 (0.00) 9 (0.04)
Other organs and organ systems 1 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.00)
Unspecified 26 (0.11) 0 (0.00) 1 (0.13) 0 (0.00) 1 (0.18) 27 (0.11)
Total anomalies included in the analysis 282 (1.22) 9 (1.63) 10 (1.35) 7 (1.81) 10 (1.76) 301 (1.23)
Babies with at least two minor anomalies 40 (0.17) 3 (0.54) 0 (0.00) 2 (0.52) 0 (0.00) 43 (0.18)
Babies with major anomalies (not
including two minor anomalies)
176 (0.76) 2 (0.36) 8 (1.08) 2 (0.52) 8 (1.41) 186 (0.76)
Babies with major anomalies (major or
two minor anomalies)
187 (0.81) 5 (0.91) 8 (1.08) 4 (1.03) 8 (1.41) 200 (0.82)
Exclusion and inclusion criteria were based on the WHO Birth Defect Panel. Babies were assessed by surface exams, and functional or internal defects
requiring additional test/examination could not be detected unless obvious without such examination.
aThe putative embryo sensitive weeks for artemisinin extrapolated from animal data. There is no suspected embryo sensitive period for quinine.
https://doi.org/10.1371/journal.pmed.1002290.t003
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treatment) (first-trimester ACT versus quinine: aHR = 0.55 [95% CI 0.15, 2.02], p = 0.370, for
the model including HIV as a categorical variable with unknown and aHR = 0.57 [95% CI
0.15, 2.15], p = 0.335, for the model with imputed missing HIV data; S1 Table).
Discussion
To our knowledge, this meta-analysis provides the most comprehensive and up-to-date analy-
sis of the potential effects of inadvertent or intentional treatment with artemisinin derivatives
in the first trimester of pregnancy and includes results from 1,664 well-documented pregnan-
cies followed prospectively after artemisinin (717) or quinine (947) treatment in the first
trimester.
We found no evidence that the artemisinin-associated embryotoxicity observed in cross-
species animal models (embryolethality and congenital anomalies [3]) was present in human
pregnancies. The available data provide no evidence of an increased risk of miscarriage or still-
birth among pregnancies with a confirmed first-trimester artemisinin treatment compared to
pregnancies with quinine or no antimalarial treatment. Restricting exposures to the hypothe-
sized artemisinin embryo sensitive period also indicates no difference in pregnancy loss
between artemisinin and quinine treatment, although the number of women and events con-
tributing to this secondary analysis was smaller and the available data can exclude only an
increase in risk of miscarriage greater than 2.0-fold (Fig 2) and an increase in risk of stillbirth
greater than 2.1-fold (Fig 3). These results were supported by the post hoc multivariate net-
work meta-analysis of pregnancy loss that combined the results of miscarriage and stillbirth
into a single effect estimate. The results for major congenital anomalies should be interpreted
with caution due to small numbers of events. Nevertheless, the data so far indicate no differ-
ence in the prevalence of major congenital anomalies between treatment groups.
Consistent with the known adverse effects of malaria in pregnancy [17,18,22,23], our results
indicate that pregnancies treated with quinine in early pregnancy were associated with an
increased risk of miscarriage compared to pregnancies not requiring treatment for malaria.
There was no such significant association for women treated with an artemisinin. This second-
ary analysis should be interpreted with caution as it is likely confounded by malaria, which is
itself a risk factor for miscarriage (i.e., confounding by indication). It is possible that the
increased risk of miscarriage associated with quinine reflects inadequately treated malaria
resulting from the known drawbacks of oral quinine, including a lengthy 7-d treatment course
with three-times-daily dosing, low tolerability, and associated poor compliance [19,40–42].
However, due to limited information on the malaria episodes being treated (including labora-
tory confirmation of malaria, parasitemia, and severity) from the African sites and unmea-
sured factors affecting health-seeking behaviors and clinician treatment decision-making, it is
not possible to know whether such an effect is due to quinine or the severity of the underlying
infection.
Our results suggest that the ACT class of antimalarials should be considered for treatment
of malaria in the first trimester. ACTs remain the most effective antimalarials to date, are well
tolerated, and are widely available. Trials in Southeast Asia, South America, and Africa found
that artemisinins performed better than quinine for the treatment of severe malaria [43],
uncomplicated malaria in non-pregnant adults [40], and malaria in the second and third tri-
mester of pregnancy [19]. Quinine has been used since the 17th century [40] and is thought to
be safe in pregnancy although there have not been any formal studies in early pregnancy
assessing its safety and efficacy [44]. Though WHO recommends the combination of quinine
and clindamycin, this combination is rarely used in practice due to high cost [45] and the low
availability of clindamycin in malaria endemic countries. Our results also suggest that oral
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quinine, even as monotherapy, was not commonly used for first-trimester malaria in the Afri-
can sites, and the number of documented quinine treatments was relatively small compared to
treatment with artemether-lumefantrine. More studies are needed to understand the reasons
behind this prescription pattern.
The power to exclude an increased risk of congenital anomalies with artemisinin treatment
was limited in the current study. A sample size calculation suggested that 1,180 exposed cases
(with a ratio of 1 exposed:4 unexposed and a background anomaly rate of 0.9%) would be
enough to detect a doubling of risk of any major congenital anomaly detectable by surface
examination. This is double the number of first-trimester artemisinin exposures presented in
this paper (n = 551 for this endpoint). To exclude a 2-fold increase in the risk of a specific
defect with an estimated background rate of 1/1,000, 10,748 first-trimester artemisinin treat-
ments and 42,992 untreated pregnancies would be needed [46]. Such numbers will only be
achievable using multiple sentinel sites over a decade and by pooling data in a global registry.
Furthermore, no study has been designed to assess cardiovascular defects, which were detected
as a potential problem in animal reprotoxicity studies in newborns, or any other internal
defects due to the unavailability of appropriate equipment and expertise in the areas where the
burden of malaria in pregnancy is highest.
A strength of this meta-analysis is the ability to standardize analyses across studies, includ-
ing definitions of the embryo sensitive period, definitions of what constituted a confirmed
treatment, and use of left truncation in the survival analysis for miscarriage [47] to avoid bias
when gestational age at exposure and enrollment varied between comparison groups [48]. Sev-
eral important limitations should be noted. We cannot account for potential confounding by
indication nor by disease severity as these data were not available in the African studies. Infor-
mation on malaria confirmation is important as malaria-infected cells could be at less risk of
artemisinin toxicity [11]. It is therefore reassuring that the results from the adjusted models
from Thailand, where this information was captured and women were recruited at earlier ges-
tation overall, were similar to those of the African studies. While the artemisinin treatments
from the African IPD analysis were predominantly artemether-lumefantrine (95%, 501/534)
and the remaining 33 were artesunate-amodiaquine, all from Burkina Faso, artemisinin treat-
ments from the SMRU included a wider range of regimens (mefloquine-artesunate, arte-
mether-lumefantrine, artesunate-clindamycin, artesunate monotherapy, and
dihydroartemisinin-piperaquine). This limits our ability to assess the effect of individual regi-
mens, with the exception of artemether-lumefantrine. Evaluation of additional potential con-
founders was limited due to some missing data (e.g., previous pregnancy loss and HIV status),
and potential for drug–drug interactions, such as between antimalarials and antiretrovirals,
could not be assessed due to limited statistical power and incomplete information on antiretro-
viral treatment. Furthermore, dose–response effects could not be assessed due to the small
numbers that had more than one artemisinin-based treatment in the first trimester (n = 5 for
the SMRU and n = 9 across the African sites). Misclassification between miscarriage and still-
birth could have occurred due to errors in gestational age assessment and lack of data on the
precise date of fetal death relative to date of expulsion/delivery. Furthermore, induced abor-
tions could have been misclassified as miscarriage, but this is unlikely to differ by exposure
group. Despite all sites having procedures in place to systematically detect external congenital
anomalies at birth, the type of training, staff cadre, and timing of assessment may have affected
the sensitivity of detection rate. Despite these limitations, the results reflect “real-life” effective-
ness of artemisinin versus quinine, and the homogeneity of the findings across the studies pro-
vides further reassurance.
Despite the high burden of malaria in pregnancy, with an estimated 125 million at risk of
infection annually in malaria endemic regions globally [49], fewer than 1,700 episodes of first-
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trimester quinine or artemisinin treatment have been documented prospectively with a known
pregnancy outcome. In total, this has taken 32 years of cumulative and collective efforts since
the introduction of artemisinins, including 13 years for 639 treatments in Africa and 19 years
for 1,025 treatments in Asia. Up to now, conducting randomized controlled trials comparing
ACTs to quinine for confirmed malaria in the first trimester of pregnancy was considered
unethical; therefore, observational studies were the only available approach to monitor the
safety of artemisinin treatment in early pregnancy. We have now reached a point of equipoise,
so such a trial could be considered; however, randomized trials would not provide the sample
size required to be informative on the risk of congenital anomalies. No single method can cap-
ture all desired data needed to make appropriate risk–benefit assessments of a drug used in
pregnancy. A combination of different methods and data sources is the only feasible approach
to gather the most complete picture of the potential developmental toxicity of a drug. The
numbers required for the assessment of congenital anomalies could only be achieved through
the combination of data across multiple sites. Identification of sentinel sites able to capture
reliable data on drug exposure and pregnancy outcomes through a standard protocol is essen-
tial for safety signal detection and characterization [31,46]. Such an approach could be used
for the evaluation of a wide variety of medications that are used during pregnancy and estima-
tion of the risk of the spectrum of adverse pregnancy outcomes. However, depending on the
recruitment strategy, assessment of miscarriages might not be feasible without introducing
dedicated efforts to detect these.
Conclusions
In this study, we found that first-trimester use of artemisinin derivatives was not associated
with an increased risk of miscarriage or stillbirth compared to quinine. The data to date also
indicate no difference in the prevalence of major anomalies between treatment groups in early
pregnancy, although the numbers of major anomalies were small. Three-day ACT regimens
are currently recommended to treat malaria in the second and third trimester. Expanding
ACT recommendations to include the first trimester may outweigh the adverse outcomes of
partially treated malaria due to poor adherence to 7-d oral quinine regimens in early
pregnancy.
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